Cell metabolism now appears as an essential regulator of immune cells activation. In 4 particular, TLR stimulation triggers metabolic reprogramming of dendritic cells (DCs) with an 5 increased glycolytic flux, whereas inhibition of glycolysis alters their functional activation. 6 The molecular mechanisms involved in the control of glycolysis upon TLR stimulation are 7 poorly understood for human DCs. TLR4 activation of human monocyte-derived DCs 8 (MoDCs) stimulated glycolysis with an increased glucose consumption and lactate 9 production. Global hexokinase (HK) activity, controlling the initial rate-limiting step of 10 glycolysis, was also increased. TLR4-induced glycolytic burst correlated with a differential 11 modulation of hexokinase isoenzymes. LPS strongly enhanced the expression of HK2, 12 whereas HK3 was reduced, HK1 remained unchanged and HK4 was not expressed. 13 Expression of the other rate-limiting glycolytic enzymes was not significantly increased. 14 Exploring the signaling pathways involved in LPS-induced glycolysis with various specific 15 inhibitors, we observed that only the inhibitors of p38-MAPK (SB203580) and of HIF-1α DNA 16 binding (Echinomycin) reduced both the glycolytic activity and production of cytokines 17 triggered by TLR4 stimulation. In addition, LPS-induced HK2 expression required p38-MAPK-18 dependent HIF-1α accumulation and transcriptional activity. TLR1/2 and TLR2/6 stimulation 19 increased glucose consumption by MoDCs through alternate mechanisms that are 20 independent of p38-MAPK activation. TBK1 contributed to glycolysis regulation when DCs 21 were stimulated via TLR2/6. Therefore, our results indicate that TLR4-dependent 22 upregulation of glycolysis in human MoDCs involves a p38-MAPK-dependent HIF-1α 23 3 accumulation, leading to an increased hexokinase activity supported by enhanced HK2 1 expression. 2 3 4
Cell metabolism now appears as an essential regulator of immune cells activation. In 4 particular, TLR stimulation triggers metabolic reprogramming of dendritic cells (DCs) with an 5 increased glycolytic flux, whereas inhibition of glycolysis alters their functional activation. 6 The molecular mechanisms involved in the control of glycolysis upon TLR stimulation are 7 poorly understood for human DCs. TLR4 activation of human monocyte-derived DCs 8 (MoDCs) stimulated glycolysis with an increased glucose consumption and lactate 9 production. Global hexokinase (HK) activity, controlling the initial rate-limiting step of 10 glycolysis, was also increased. TLR4-induced glycolytic burst correlated with a differential 11 modulation of hexokinase isoenzymes. LPS strongly enhanced the expression of HK2, 12 whereas HK3 was reduced, HK1 remained unchanged and HK4 was not expressed. 13 Expression of the other rate-limiting glycolytic enzymes was not significantly increased. 14 Exploring the signaling pathways involved in LPS-induced glycolysis with various specific 15 inhibitors, we observed that only the inhibitors of p38-MAPK (SB203580) and of HIF-1α DNA 16 binding (Echinomycin) reduced both the glycolytic activity and production of cytokines 17 triggered by TLR4 stimulation. In addition, LPS-induced HK2 expression required p38-MAPK-18 dependent HIF-1α accumulation and transcriptional activity. TLR1/2 and TLR2/6 stimulation 19 increased glucose consumption by MoDCs through alternate mechanisms that are 20 independent of p38-MAPK activation. TBK1 contributed to glycolysis regulation when DCs 21 were stimulated via TLR2/6. Therefore, our results indicate that TLR4-dependent 22 upregulation of glycolysis in human MoDCs involves a p38-MAPK-dependent HIF-1α 23 Introduction 1 2 TLRs are common sensors expressed by dendritic cells (DCs) recognizing pathogen-3 associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), 4 initiating an appropriate immune response to fight infection (1) . TLR signaling triggers 5 human DC maturation, promoting the secretion of pro-inflammatory cytokines, inducing the 6 expression of co-stimulatory molecules so that DCs acquire the ability to stimulate naïve T 7 cells (2). TLR4 is a receptor for Gram-negative bacteria LPS (3). This receptor can be also 8 activated by other microbial ligands such as viral proteins (4) (5) (6) and by DAMPs, such as 9 HMGB1 (high-mobility group box 1) (7) or oxidized phospholipids (8) . TLR4 is also involved in 10 the sensing of nutrients and metabolic stress. Indeed, saturated free fatty acids (FFA) can 11 activate TLR4 signaling via their binding to the hepatokine Fetuin A which is a TLR4 ligand (9) . 12 Its increased production in steatotic and inflamed liver contributes to the secretion of 13 inflammatory cytokines by monocytes and adipose tissue (10). By regulating the expression 14 of many genes involved in innate immunity and metabolic reprogramming (11) , TLR4 is at 15 the crossroads of innate immunity and metabolic inflammation (12) and is involved in the 16 pathogenesis of metabolic diseases such as obesity and type-2 diabetes (13). 17 Glucose is a major nutrient for cellular bioenergetics production. Glycolysis converts glucose 18 to pyruvate by a series of enzymatic reaction steps, generating 2 moles of ATP per mole of 19 glucose. Intermediary metabolites of glycolysis are precursors also fueling the pentose-20 phosphates, lipids and amino-acids pathways (11) . Three rate-limiting enzymes are 21 controlling the glycolytic flux. The first one, the hexokinase (HK), controls the conversion of 22 glucose to glucose-6-phosphate. There are 4 isoenzymes of HK (HK-I, II, III, IV) encoded by 4 23 different genes (HK 1, 2, 3, 4 is increased to face energetic needs (14) . However, activation of glycolysis can also occur 10 under aerobic conditions and Otto Warburg first discovered that tumor cells have a high rate 11 of glycolysis and that most pyruvate is converted to lactate, even when oxygen is available 12 (15). Both innate and adaptive immune cells can shift to aerobic glycolysis upon stimulation. 13 Cell metabolism is now appreciated as a key regulator of T cell differentiation, modulating 14 effector and memory functions (16). The transcriptional control of glycolysis in T cells mainly 15 rely on the expression of hypoxia-inducible factor 1 (HIF-1) and the proto-oncogene MYC 16 (17) . Accumulation of HIF-1α in normoxic conditions has been observed in several cell types 17 upon LPS stimulation (14, 18, 19) . Several molecular mechanisms may result in this 18 accumulation, including activation of the mammalian target of rapamycin complex 1 19 (mTORC1) (20). In primary human plasmacytoïd DCs, increased glycolysis was found to play a 20 key role in the regulation of anti-viral functions, including IFN-α production (21). Tolerogenic 21 DCs also show a metabolic signature characterized by high mitochondrial respiration and 22 glycolytic capacity (22) . TLR4 stimulation of DCs or macrophages results in increased 23 glycolytic activity, an essential process for their proper activation (23-29). Indeed, a 24 metabolic reprogramming to aerobic glycolysis was described to be associated to a 1 proinflammatory M1 phenotype of murine macrophages, whereas glycolytic activity was 2 unchanged in alternate activated M2 macrophages (11, 30) . The molecular mechanisms 3 involved in glycolysis upregulation upon TLR4 stimulation remain to be clarified and may 4 differ according to cell types and functions.
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In murine bone marrow-derived DCs (BM-DCs), two different molecular pathways have been 6 depicted for glycolytic reprogramming upon TLR4 stimulation. Activation of TBK1-IKKε and 7 AKT kinases was found to control the early increase of glycolysis, favoring mitochondrial 8 translocation of HK-II, fueling the TCA cycle and fatty acids synthesis (24). In these DCs, the 9 late increase in glycolytic metabolism was proposed to be a survival response to maintain 10 ATP production despite the inhibition of oxidative phosphorylation by NO, produced by the 11 inducible NO synthase (25). This pathway is unlikely to be involved in human DCs since this 12 enzyme is not expressed (31) and NO production could not be detected in these cells (27) . 13 Studies exploring the molecular mechanisms involved in the regulation of glycolysis in 14 primary human DCs are lacking for a better understanding of the reciprocal interactions 15 between cellular metabolic activity and the functional DC activation state. 16 Therefore, we explored the pathways involved in the control of glycolytic activity upon TLR4 dissolved in sterile PBS. FP7 was synthesized from commercially available D-glucose by 5 multistep organic synthesis according to published procedures (32) . The purity of the 6 molecule was assessed by nuclear magnetic resonance and mass spectrometry analysis. A 5 7 mM stock solution of FP7 was prepared in ethanol/ DMSO 1:1 and conserved at -20°C. 8 The inhibitors SB203580, SP600125, PD98059, BX795, and LY294002 purchased from 9 InvivoGen, Rapamycin, provided by Calbiochem (San Diego, CA, USA) and HIF-1DNA-10 binding inhibitor, Echinomycin, provided by Cayman Chemical (Ann Arbor, MI, USA), were 11 dissolved in sterile culture grade DMSO and stored at -20°C. AZD5363 and SC75741 were 12 purchased from Selleckchem (Houston, TX, USA) prepared in DMSO and stored at -80°C. 13 Pepinh MYD, pepinh TRIF and pepinh control (Ctl) purchased from Invivogen were dissolved 14 in PBS and stored at -20°C. 15 Glucose uptake was measured by incorporation of 2-Deoxy-2-[(7-nitro-2, Cytokine assays 8 Clarified culture supernatants were collected 24h after treatment and stored at -20°C. IL-8, 9 MIP-1β, IL-6, IL-10, IL-12p40, TNFα were assayed using quantitative cytokine specific 10 Cytometric Bead Array Flex Sets (BD Biosciences). For total RNA isolation, 6h-or 24h-treated DCs were collected and washed twice with PBS. 19 RNA extraction was performed using the NucleoSpinRNA Mini kit from Macherey Nagel 20 according to the manufacturers' instructions. cDNA were synthetized using RNA-to-cDNA kit 21 (Applied Biosystems, Villebon sur Yvette, France) before quantitative PCR experiment using 22 the following primers: for HK1 DNA forward 5'-gcctcttatttgaagggcgg-3', reverse 5'-23 gacacagtcatcatcggacg-3', for HK2 DNA forward 5'-tcccctgccaccagacta-3', reverse 5'-24 tggacttgaatcccttggtc-3', for HK3 DNA forward 5'-CATCGTGGACTTCCAGCAGAAG-3', reverse Hexokinase activity assay 15 The method used for extracting HK from DCs was adapted from Kuang et al. (35) and the 16 assay was a modification of that described by Ramière et al. (36) . -80°C frozen pelleted cells 17 were homogenized (100 µl / 2 x 10 6 cells) in pre-cooled homogenization buffer HCl, 250 mM sucrose, 5 mM EDTA (pH 7.4), 5 mM 2-mercaptoethanol, 10 mM glucose, 0.2% 19 Triton X-100). After a 20 min incubation on ice, homogenates were pulse-sonicated 5 sec at 20 half power of the device (EpiShear Probe Sonicator, Active Motif, La Hulpe, BE).
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Homogenates were then centrifuged at 500 g for 20 min at 4°C. Supernatants were 22 immediately used for determination of HK activity. HK activity was measured 23 spectrophotometrically through NADP+ reduction in the glucose- Phosphoprotein detection 9 Day 6 DCs were pre-treated in water bath at 37°C with inhibitors for 30 min before TLR 10 ligands addition for 15 min. TLR stimulation was stopped on ice before two cold PBS-washes. 11 Then cells were fixed with cytofix solution (BD Biosciences) for 10 min at 37°C before 
TLR4 stimulation induces glycolytic burst and upregulation of HK2 expression and activity
3 Monocyte-derived DCs (MoDCs) stimulated by LPS for 24h showed an increased glucose 4 consumption and lactate production compared to non-stimulated MoDCs (Fig 1A-B) , 5 indicative of an increased glycolytic activity. The amplitude of this glycolytic burst was 6 dependent on the dose of LPS and was statistically significant from 10 ng/ml to 1000 ng/ml. 7 We previously characterized a selective TLR4 antagonist, FP7, inhibiting the secretion of pro-8 inflammatory cytokines by LPS-stimulated MoDCs with an IC 50 below 1 µM (27). FP7 also 9 prevented LPS-induced secretion of IFN-β ( Suppl Fig 1) , suggesting that FP7 blocked both 10 endosomal TRIF-dependent and surface MyD88-dependent TLR4 signaling (37). Since FP7 11 competes with LPS for binding to the TLR4 MD-2 subunit (32, 38) , and prevents ligand-12 mediated TLR4 internalization (F. Facchini et al., manuscript in preparation) , these results 13 suggest that FP7 may not directly inhibit endosomal TLR4 signaling but rather inhibits 14 upstream activation of TLR4 receptor by LPS. Treatment of cells with 10 µM FP7 prior to LPS 15 stimulation prevented the increase in glucose consumption and lactate production triggered 16 by LPS from 0.1 to 100 ng/ml ( Fig 1A-B) , showing that this glycolytic regulation was TLR4-17 dependent. At the highest LPS concentration (1000 ng/ml), FP7 did not totally block the 18 increase of the glycolytic flux, consistent with previous data (27). Using a fluorescent 19 deoxyglucose as a non-hydrolysable substrate of HK (2-NBDG), we measured the capacity of 20 glucose uptake by the cells after 6h and 24h LPS-stimulation. No difference in the uptake 21 could be detected between control and LPS-stimulated MoDCs (Fig 1C) , indicating that 22 increased glycolytic activity in TLR4-stimulated MoDCs was not due to an increased 23 availability of intracellular glucose. We thus analyzed the expression of the 3 rate-limiting 24 glycolytic enzymes, HK, PFK and PKM, at the mRNA level. Compared to control cells, HK2 was 1 strongly induced in LPS-stimulated MoDCs while HK3 was reduced ( Fig 1D) . HK1 remained 2 unchanged, whereas HK4 was not expressed in MoDCs. In contrast to PFKM and PKM1, PFKL, 3 PFKP and PKM2 were highly expressed in MoDCs but not significantly augmented upon LPS 4 stimulation (Fig 1E-F) . The data indicate that the expression profile of HK isoenzymes is 5 modified upon TLR4 stimulation. This new expression profile correlates with a major 6 increase in hexokinase activity in total lysates of LPS-stimulated MoDCs compared to 7 unstimulated cells ( Fig 1G) . expression of phenotypic maturation marker and glucose consumption were measured. 19 As expected, p38-MAPK inhibitor SB203580 (SB) inhibited the secretion of IL-6, IL-8 and MIP-20 1β ( Fig 3A) molecule HLA-DR, of co-stimulation molecules CD86, CD40, and of the CD54 adhesion 23 molecule was analyzed by FACS ( Fig 3B-C) . SB significantly inhibited the expression of CD86, 24 CD54 and reduced although not significantly CD40 expression compared to LPS-stimulated 1 MoDCs. SC75741 and AZD5363 mainly reduced CD54 expression. The other inhibitors did not 2 induce significant changes in MoDCs phenotype. 3 Among the tested inhibitors, p38-MAPK inhibitor SB was the most potent inhibitor of the 4 glycolytic burst triggered by LPS ( Fig 4A) . Echinomycin, which prevents DNA binding of HIF-5 1α to Hypoxia Response Elements, also significantly reduced the action of LPS on glucose 6 consumption ( Fig 4A) . The other drugs did not significantly reduce glucose consumption by 7 LPS-stimulated cells. The inhibitors showed no significant toxicity ( Fig 4B) . These results 8 indicate that p38-MAPK and HIF-1α are major actors of the increased glucose consumption 9 triggered by LPS and suggest an unexpected link between them. By blocking dimerization of 10 MyD88 or TRIF, we observed that both TLR adaptors were recruited to trigger the glycolytic 11 burst upon TLR4 stimulation (Suppl Fig 2) , pointing to a common downstream pathway that 12 may involve TRAF6, a key component upstream of p38-MAPK.
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BX795 altered the secretion of cytokines and/or the expression of phenotypic marker 14 without affecting LPS-triggered regulation of glycolysis ( Fig 3A-C, 4A) . In contrast, treatment 15 by the HIF-1α antagonist Echinomycin resulted in both reduced LPS-induced glycolytic 16 activity and IL8 secretion ( Fig 3A, 4A) , indicating that reduced glycolytic burst may contribute 17 to the reduction of cytokines secretion or maturation markers expression. Accordingly, we 18 previously reported that inhibition of the glycolytic burst by 2-deoxyglucose (2-DG) 19 treatment, affected both cytokines secretion and phenotypic markers expression induced by 20 TLR4 stimulation (27). 23 MoDCs stimulation by LPS resulted in a strong increase of HK2 expression that can be 1 detected as soon as 6h after LPS addition (Fig 5A) . At this early time, HK3 expression was 2 unchanged compared to control cells while it was decreased 24h post stimulation ( Fig 1D) . 3 HK1 remained constant ( Fig 5A) . Using the inhibitors that reduced glucose consumption by 4 LPS-treated MoDCs, we found that SB and Echino strongly reduced HK2 transcription 5 induced by LPS ( Fig 5A) . SB treatment of MoDCs inhibited the phosphorylation of p38-MAPK, 6 without affecting the phosphorylation of NF-B and JNK, as expected ( Fig 5B) . HIF-1α is an 7 important transcription factor for the regulation of HK2 expression (41). It is constitutively 8 expressed and the regulation of its degradation controls its accumulation and activity (42, 9 43) . In total lysates from MoDCs, we observed that LPS stimulation for 24h resulted in an 10 important accumulation of HIF-1α that was prevented by SB treatment (Fig 5C-D) . Therefore 11 HIF-1α accumulation triggered by LPS appeared to be dependent on p38-MAPK activation. As other bacterial ligands can induce MoDCs functional activation, we tested the effect of 16 PGN and Pam, the ligands for TLR2/6 and TLR1/2 respectively, on glucose consumption. Both 17 TLR ligands significantly increased glucose consumption of MoDCs although to a different 18 level ( Fig 6A) . PGN, like LPS, induced a strong increase of glucose consumption, while Pam 19 was less efficient (50% of the LPS increase). Inhibition of glucose consumption by SB reached 20 70% and 65% when it was induced by LPS-TLR4 and Pam-TLR1/2 respectively, whereas it was 21 only 35% after PGN-TLR2/6 stimulation. P38-MAPK phosphorylation was detected upon 22 stimulation of all these TLRs and was inhibited by SB ( Fig 6B) . The inhibition of this kinase by 23 SB strongly impacted the secretion of cytokines triggered by TLR4. Cytokines secretion 24 elicited by TLR2/6 or TLR1/2 tended to be reduced by SB but to a lesser extend ( Fig 6C-D) . 1 Therefore, the amplitude of glycolytic burst and of its inhibition by SB indicates that 2 glycolysis regulation by TLRs is unlikely to result from a common mechanism. 3 Under the same conditions, we analyzed cells content in HIF-1α and observed that TLR1/2 4 and TLR2/6 stimulation of MoDCs, by Pam or PGN respectively, resulted in a weak 5 accumulation of HIF-1α compared to TLR4 stimulation by LPS ( Fig 6E) . SB treatment did not 6 modify the amount of HIF-1α upon TLR2/6 and TLR1/2 in contrast to TLR4 stimulation. In line 7 with this observation, the inhibition of HIF-1α transcriptional activity by Echinomycin did not 8 significantly impact glucose consumption triggered by PGN and Pam (Fig 7) , suggesting that 9 this pathway does not play a major role in glycolysis regulation by TLR2/6 and TLR1/2. As 10 expected, glycolysis inhibition by 2-DG, reduced glucose consumption triggered by PGN and 11 Pam. The screening of other inhibitors showed a weak contribution of TBK1 in the 12 upregulation of glucose consumption by PGN, whereas neither PI3K nor AKT or mTOR 13 inhibition significantly altered the glycolytic burst (Fig 7) . The screening did not allow the 14 identification of a pathway involved in the glycolytic regulation upon TLR1/2 stimulation by 15 Pam. 16 Therefore, the regulation of HIF-1α stabilization upon PGN or Pam stimulation did not 17 depend on p38-MAPK activation. TLR2/6 and TLR1/2 stimulation resulted in a p38-18 independent HIF-1α slight accumulation and increased glucose consumption. In contrast 19 TLR4 regulation of glycolysis in human MoDCs implicates p38-MAPK-dependent stabilization 20 of HIF-1α (Fig 8) . immunostimulatory MoDCs and found that tolerogenic DCs had the highest glycolytic 12 capacity upon ATP synthase inhibition, whereas they had a similar glycolytic rate to that of 13 LPS-stimulated MoDCs (22) . Similarly to us, they found that LPS stimulation enhanced lactate 14 secretion and glycolytic rate of MoDCs without affecting glucose uptake. 15 Previous results with mouse DCs showed that activation of TBK1-IKK and AKT kinases 16 controlled the early increase in glycolysis triggered by TLR4 (24). In our experimental 17 conditions, TBK1 and AKT inhibitors did not impact the glycolytic activity of LPS-stimulated 18 MoDCs ( Fig 4A) . Moreover, no phosphorylation of AKT could be detected after LPS 19 stimulation of MoDCs (cf. Suppl Fig S3) . Pam induced AKT phosphorylation (cf. Suppl Fig S3) , 20 however inhibiting PI3K or AKT kinases did not significantly alter the glycolytic 21 reprogramming of MoDCs upon TLR1/2 or TLR2/6 stimulation (Fig 7) . TLR2/6 stimulation by 22 PGN induced an important increase of glucose consumption by MoDCs, which was 23 significantly reduced by TBK1 inhibition (Fig 7) . This is consistent with recent data showing 24 that TBK1 is involved in TLR2 signaling (46). Our results indicate that TBK1 contributed to this 1 metabolic regulation, by mechanisms different from those described for murine BM-DCs (24) 2 since AKT was not involved. Thus, glycolysis activation by TLR4, TLR2/6 and TLR1/2 appears 3 to engage distinct signaling pathways in human MoDCs. 4 Major differences in the regulation of glycolytic activity have been reported between mouse 5 and human DCs. mTOR was shown to be an important regulator of LPS-induced murine DC 6 activation and glucose consumption, but not in human myeloid DCs (47). In agreement with 7 these results, we observed that the mTORC1 inhibitor Rapamycin did not impact the 8 upregulation of glycolysis upon LPS stimulation in MoDCs (Fig 4) . Moreover, human MoDCs 9 and macrophages do not produce any NO (27, 31) , an inhibitor of the oxidative 10 phosphorylation that was shown to boost the glycolytic pathway in mouse DCs (25). 11 Therefore, results obtained from murine BM-DCs or macrophages cannot be readily 12 extrapolated to human DCs. 13 Previous works indicated that LPS stimulation of mouse BM-DCs and human MoDCs resulted 14 in HIF-1α accumulation (14, 18, 19) . In normoxia, HIF-1α degradation is regulated by 15 hydroxylation of proline and asparagine residues by prolyl-hydroxylase domain enzymes 16 (PHDs). The interaction of the von Hippel-Lindau (VHL) factor with these hydroxylated 17 residues, recruits an E3 ubiquitin-ligase that targets HIF-1α to the proteasome for 18 degradation (48). Hypoxia induces HIF-1α accumulation via PHD inhibition due to the lack of 19 its oxygen cosubstrate (18). However, data describing the molecular mechanisms controlling 20 HIF-1α accumulation in primary cells, upon inflammation in normoxic conditions are sparse.
LPS-induced HK2 expression requires p38-MAPK dependent HIF-1 stabilization
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In murine macrophages, LPS-induced HIF-1α accumulation seems to require NF-κB-and ERK- 22 dependent transcriptional events (49, 50) . In other studies, ROS production and succinate 23 accumulation upon LPS stimulation inhibit PHD activity thus increasing HIF-1α stability (51, 24 52). In murine BM-DCs, sequestration of iron, a PHD co-factor, stabilizes HIF-1α upon LPS 1 stimulation (18). The AKT-mTOR-HIF-1α pathway was found to upregulate glycolysis in 2 murine monocytes (20). In human MoDCs, our results point to a different molecular 3 mechanism involving a p38-MAPK dependent HIF-1α stabilization. This is crucial to the 4 glycolytic regulation upon TLR4 activation but p38 activity is not involved in the stabilization 5 of HIF-1α upon TLR2/6 stimulation. Although, p38-MAPK phosphorylation is induced by 6 TLR4, TLR1/2 and TLR2/6 ( Fig 6B) , the consequence on HIF-1α accumulation varies. This 7 differential regulation points to an indirect control of HIF-1α stability by p38-MAPK. The 8 molecular mechanism explaining the differential regulation of HIF-1α accumulation in 9 MoDCs according to TLR stimulation remains to be discovered. In tumor cells, previous 10 studies showed that p38-MAPK could contribute to HIF-1α stabilization (53, 54) . One 11 possible mechanism proposed by Khurana et al. (55) in mouse embryonic fibroblasts, is that 12 the Ring Finger ubiquitin ligase Siah2 can be phosphorylated by p38-MAPK, increasing the 13 degradation of PHD3, therefore reducing HIF-1α degradation. 14 In both mouse and human models, HIF-1α stabilization alone was not sufficient to induce DC 15 maturation, but it positively contributes to their functionality upon TLR stimulation (14, 19) . 16 In mouse BM-DCs, HIF-1α induction by the combined effects of LPS and hypoxia plays a key 17 role in the regulation of glucose consumption, DC maturation and their ability to stimulate 18 allogeneic T cells (14) . In human MoDCs, HIF-1α stabilization could synergize with TLR 19 stimulation to favor maturation (19) . 20 The HIF-1α DNA-binding inhibitor, Echinomycin, reduced the secretion of IL-8 by LPS-21 stimulated DCs (Fig 3A) . IL-8 secretion highly depends on enhanced gene transcription and 22 IL-8 promoter mainly recruits NF-B, AP-1 and NRF (56) but does not contain HIF response 23 elements. The reduction of IL-8 secretion by Echinomycin treatment may thus result from 24 the limitation of the glycolytic burst of MoDCs. Indeed, previous results indicate that 1 hexokinase inhibition by 2-DG suppressed increased glycolysis and reduced the secretion of 2 many cytokines and especially 29) . By reducing the glycolytic 3 burst triggered by LPS, Echinomycin may impede optimal maturation and especially impact 4 maturation processes that require active gene transcription, such as cytokine neosynthesis. 5 Reduced expression of phenotypic maturation markers of MoDCs was observed with 2-DG 6 which strongly inhibits glycolysis (27), but not with Echinomycin which only partially reduces 7 LPS-induced glycolytic burst (Fig 3B-C) . Glycolysis inhibition by 2-DG strongly reduced the 8 secretion of inflammatory cytokines and altered the expression of some phenotypic 9 maturation markers, triggered by PGN and Pam (Suppl Fig 4) , reinforcing previous results 10 highlighting the importance of the glycolytic burst for TLR-induced DC maturation (27, 29) . 11 Reduction by Echinomycin of both the glycolytic burst (Fig 7) and the secretion of pro-12 inflammatory cytokines (Suppl Fig 4) triggered by PGN and Pam was not statistically 13 significant. Even though we cannot totally exclude a contribution of HIF-1α, this pathway did 14 not appear to play a major role in glycolysis regulation by TLR2/6 and TLR1/2. 15 Increasing evidence indicates that metabolic pathways play important roles in the fine 16 tuning of immune cell functions. Detailed studies have been conducted on T cell 17 differentiation and mouse macrophage functional polarization according to their metabolic 18 state (11) . The signaling of many receptors can result in the regulation of metabolic 19 pathways, by controlling the activation of transcription factors and the expression of producing glucose-6-phosphate which is a precursor for glycolysis but also for the pentose-10 phosphate and hexosamine biosynthetic pathways. Thus, HK plays a key role in glycolysis 11 and biosynthetic pathways. HK-II is the predominant isoenzyme in insulin-sensitive tissues 12 such as heart, adipose tissue and skeletal muscle and it is also upregulated in many types of 13 tumors associated with enhanced aerobic glycolysis (Warburg effect), suggesting that it is a 14 major regulator of the glycolytic rate in these cells (59 
